160 billion yuan! Abbott acquires St. Jude! The pattern of medical device circle saday!

Medicine Network April 29th , the world is changing fast, so fast that you can't see at alllast summer, it was reported that Abbott would buy StJude for $25 billion, but on the same day Abbott denied itIt was also nicknamed "The Ballad of the Day", StJude also paid $3.4 billion in cash to buy Thoratec, the medical device makerheart, in a deal completed in OctoberIt also reveals that the company will not be acquiredbut after half a year, the rumor came true againOn the evening of April 28, Beijing time, Reuters reported that Abbott Pharmaceuticals had agreed to buy StJude Medical For about $25 billionJude Medical)Converted into RMB, the acquisition cost more than 160 billion yuan-related acquisitions will be made in the form of a cash-for-share exchange and are expected to be completed in the fourth quarter of this yearthe deal will combine StJude's strengths in heart failure treatment equipment, cardiac catheters and defibrillators with Abbott's strengths in coronary artery intervention and valve repair, and is expected to generate $500 million in sales and operating income by 2020 why did Abbott buy St Jude so much? because St Jude is also a cow! St Jude Medical was founded in 1976 and is headquartered in St Paul, Minnesota, the capital of medical technology The company's business covers five areas, including cardiac rhythm management, cardiac electrophysiology, cardiac surgery, cardiovascular intervention almost cardiovascular care, and neuroregulation products include: pacemakers, ICD, CRT/D, electrophysiological 3D standarding systems, ablation and diagnostic catheters, artificial heart valves and repair products, vascular push and closing systems, and neurostimulators revenue at St Jude Medical was $1.45 billion in the first quarter, up 7.7 percent from a year earlier, and net profit was $95 million, compared with $262 million a year earlier Based on this, the company's full-year revenue is about $6 billion St Jude had entered the Chinese market in 1996, but it was a lot more low-key than Abbott But St Jude is also in the top 20 among the world's medical device companies, while Abbott is in the top 10 this set of data is intuitive , Mr Covewas was acquired by Medtrony last year and made it happen in the third quarter Tocco's Fu and Medtronic reported revenue of $6.93 billion in the third quarter, up 61 percent from a year earlier, and net profit of $1.1 billion, up from $977 million a year earlier Revenue rose another 5% in the fourth quarter and the performance of Johnson and Johnson's medical device division last year, we all know that revenue, net profit both fell, the group's worst performance The decline narrowed in the first quarter, but revenue was only $6.11 billion, down 2.4 percent from a year earlier from the data, the world's largest device is already Medtroni, no longer Johnson and Johnson big acquisitions, Abbott's "Wolf Is Coming" from Medtroni to Covey to Abbott and St Jude, every one of which is American That's because the U.S medical device industry has been consolidating under pressure from hospital
and healthcare systems to cut costs the number of pending or completed mergers and acquisitions in the U.S medical device industry last year was as high as 1,007, totalling $58.9 billion Medtroni was the leader, with $49.9 billion in acquisitions As Abbott after Johnson and Medtrony, the inner shock will be no small cardiovascular field with small swallowing, Abbott chased Medtronic described St Jude's business scope and key products It is the second-largest cardiovascular medical device company, behind Medtronic and higher than Abbott's giant company In the field of cardiovascular equipment alone, Abbott's acquisition of St Judea was in fact a small swallow But can't resist Abbott's extensive scope of business, the overall strength of the company is more cattle ah evaluate is a study by MedTech that estimates the top 10 global revenues for cardiovascular medical devices in 2020 According to the report, Medtroni's revenue will reach $11.1 billion by 2020, which is not taken into account, and medtrony's revenue will reach $12.6 billion in 2020 St Jude and Abbott came in second and fourth, respectively, but far behind Medtroni now Abbott's $25 billion acquisition of St Jude, which will be included in Abbott's cardiovascular equipment division So Abbott will overtake Boston Science to take second place and go straight after Medtronic, and the gap will narrow dramatically the market landscape in the segment of cardiovascular medical devices will change acquisition of Ariel, IVD's market landscape has been changed by Abbott
in early February, Abbott announced that it would buy U.S diagnostic services provider Alere Inc for $5.8 billion, a deal that would give Abbott a global lead in bedside testing , Ariel generates more than $2.5 billion in annual sales After the acquisition, Abbott's revenue in in vitro diagnostics could reach $7 billion, surpassing Siemens and pushing Roche Abbott's strong intervention, the IVD field of market competition has been changed from in vitro diagnosis to cardiovascular medical devices, Abbott, with his strong capital strength, staged two "wolf is coming" play And then, what else is Abbott's potential to be a bully? 　　Look at Abbott's product line, with its money in one area, the first improper second do pie, is likely to target vision health and blood glucose meter areas Both of them, Johnson, were shot giants are already giants, still fighting for you to die I live And with tens of billions of dollars of giant mergers, these crazy moves are definitely not a flashin, but capital-driven expression With money also want to be richer, want to always be rich, want to dominate the market as the world's most developed countries, the United States medical device market today is the Chinese market tomorrow Not even waiting until tomorrow, because the Chinese market is also under pressure from medical institutions Under pressure, big fish swallow small fish, and even strong integration is only inevitable!